Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Primary Progressive Multiple Sclerosis (PPMS) Overview | 8 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Therapeutics under Development by Companies | 9 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Products under Development by Companies | 13 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Companies Involved in Therapeutics Development | 14 | 8 |
| F. Hoffmann-La Roche Ltd. | 15 | 1 |
| Genzyme Corporation | 16 | 1 |
| Glialogix, Inc. | 17 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 18 | 1 |
| MedDay SA | 19 | 1 |
| Santhera Pharmaceuticals Holding AG | 20 | 1 |
| Teva Pharmaceutical Industries Ltd. | 21 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 52 |
| biotin Drug Profile | 31 | 4 |
| GLX-1112 Drug Profile | 35 | 1 |
| GZ-402668 Drug Profile | 36 | 1 |
| IB-MS Drug Profile | 37 | 1 |
| ibudilast Drug Profile | 38 | 8 |
| idebenone Drug Profile | 46 | 8 |
| laquinimod sodium Drug Profile | 54 | 8 |
| masitinib Drug Profile | 62 | 14 |
| ocrelizumab Drug Profile | 76 | 5 |
| Small Molecules for Primary Progressive Multiple Sclerosis and Secondary Progressive Multiple Scleros Drug Profile | 81 | 1 |
| Stem Cell Therapy for CNS Disorders Drug Profile | 82 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Dormant Projects | 83 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Discontinued Products | 84 | 1 |
| Primary Progressive Multiple Sclerosis (PPMS) Product Development Milestones | 85 | 11 |
| Featured News &Press Releases | 85 | 1 |
| Jul 13, 2016: MediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS | 85 | 1 |
| Jun 28, 2016: Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA | 86 | 1 |
| May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial | 87 | 1 |
| Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN | 87 | 2 |
| Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis | 89 | 1 |
| Feb 17, 2016: FDA Grants Breakthrough Therapy Designation for Genentech s Investigational Medicine Ocrelizumab in Primary Progressive Multiple Sclerosis | 89 | 1 |
| Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 | 90 | 2 |
| Oct 20, 2015: Clinical trial shows first ever positive results in treating primary progressive and relapsing multiple sclerosis | 92 | 1 |
| Oct 10, 2015: More Results Released from Positive Phase III Clinical Trial of Ocrelizumab in Primary Progressive MS | 93 | 1 |
| Apr 23, 2015: Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS | 94 | 1 |
| Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting | 94 | 1 |
| Feb 01, 2015: MN-166 (ibudilast) Progressive MS Abstract Accepted for Presentation at AAN 67th Annual Meeting in Washington, DC | 95 | 1 |
| Appendix | 96 | 2 |
| Methodology | 96 | 1 |
| Coverage | 96 | 1 |
| Secondary Research | 96 | 1 |
| Primary Research | 96 | 1 |
| Expert Panel Validation | 96 | 1 |
| Contact Us | 96 | 1 |
| Disclaimer | 97 | 1 |
